China is a large country producing APIs, Active Pharmaceutical Ingredients, and many APIs are used in the formula ingredients of health food products. The quality and price of APIs are directly transmitted to downstream enterprises, and, therefore, the management of the state monopoly of APIs helps to regulate the industry. On October 13, the State Administration of Market Regulation issued the “Anti-monopoly Guidelines on the Field of APIs (Draft for Comment)”, which is now open to the public for comments until October 30, 2020. (Source: Shuzhengkangxun)

Comments are closed.